Use of Presepsin and Nitric Oxide Metabolites in Pediatric Oncology Patients with Infectious Complications

E.G. Golovnya, A.V. Sotnikov, V.N. Baykova, O.P. Petina

N.N. Blokhin Russian Cancer Research Center, Moscow

For correspondence: Sotnikov Anatoly Bjacheslavovich — Ph.D, Senior Research Officer, Department of anesthesiology and reanimatology of N.N. Blokhin Russian Cancer Research Center; e-mail:

For citation: Golovnya EG, Sotnikov AV, Baykova VN, Petina OP. Use of presepsin and nitric oxide metabolites in pediatric oncology patients with infectious complications. Intensive Care Herald. 2016;3:43–46.

Early diagnostics of infectious complications is an actual problem of modern medicine. Application of different methods of laboratory biomarkers of sepsis allows to differentiate between different pathological conditions by its severity (from SIRS to septic shock and multi-organ failure), that seems to be crucial in prognosis. Differences in concentration of presepsin (PSP) and nitric oxide metabolites (sum of nitrates and nitrites) in two groups of pediatric patient with oncological diseases are presented in current research (р < 0.05). There was no statistically significant correlation between these biomarkers in both groups of patients. Our data showed evidence that growth of concentration of PSP and simultaneous drawdown of concentration of NOx could be a factor of poor prognosis in patients with infectious complications.

Keywords: biomarkers of sepsis, pediatric oncology, presepsin, nitric oxide

Received: 06.03.2016


  1. Mayr F.B., Yende S., Angus D.C. Epidemiology of severe sepsis. Virulence. 2014; 5(1): 4–11. doi: 10.4161/viru.27372. Epub 2013 Dec 11.
  2. Samraj R.S., Zingarelli B., Wong H.R. Role of biomarkers in sepsis care. Shock. 2013; 40(5): 358–365. doi: 1097/SHK.0b013e3182a66bd6.
  3. Колесниченко А.П., Мосякин Н.А., Распопин Ю.С., Кондрашов М.А. Информативность различных биохимических маркеров сепсиса: литературные и собственные данные. Сибирское медицинское обозрение. 2015; 4: 11–17. [Kolesnichenko A.P., Mosyakin N.A., Raspopin Yu.S., Kondrashov M.A. Informativnost’ razlichnyh biohimicheskih markerov sepsisa: literaturnye i sobstvennye dannye. Sibirskoe meditsinskoe obozrenie. 2015; 4: 11–17. (In Russ)]
  4. Vincent J.L., Donadello K., Schmit X. Biomarkers in the critically ill patient: C-reactive protein. Crit. Care Clin. 2011; 27: 241–251. doi: 10.1016/j.ccc.2010.12.010.
  5. Reinhart K., Meisner M. Biomarkers in the critically ill patient: procalcitonin. Crit. Care Clin. 2011; 27: 253–263. doi: 10.1016/j.ccc.2011.01.002.
  6. Yaegashi Y., Shirakawa K., Sato N. et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J. Infect. Chemother. 2005; 11: 234–238. doi: 10.1007/s10156-005-0400-4.
  7. Shozushima T., Takahashi G., Matsumoto N. et al. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J. Infect. Chemother. 2011; 17: 764–769. doi: 10.1007/s10156-011-0254-x. Epub 2011 May 12.
  8. Lupp C., Baasner S., Ince C. et al. Differentiated control of deranged nitric oxide metabolism: a therapeutic option in sepsis? Crit. Care. 2013; 17(3): 311. doi: 10.1186/cc12538.
  9. Endo S., Suzuki Y., Takahashi G. et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: A multicenter prospective study. J. Infect. Chemother. 2013;18(6): 891–897. doi: 10.1007/s10156-012-0435-2.
  10. Liu B., Chen Y.X., Yin Q. et al. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit. Care. 2013; 17(5): R244. doi: 10.1186/cc13070.
  11. Levy M.M., Fink M.P., Marshall J.C. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care 2003; 31: 1250–1256. doi: 10.1097/01.CCM.0000050454.01978.3B
  12. Голиков П.П., Николаева Н.Ю. Метод определения нитрита/нитрата (NOx) в сыворотке крови. Биомедицинская химия. 2004; 50(1): 79–85. [Golikov P.P., Nikolaeva N.Yu. Metod opredeleniya nitrita/nitrata (NOx) v syvorotke krovi. Biomeditsinskaya himiya. 2004; 50(1): 79–85. (In Russ)]
  13. Марков Х.М. Роль оксида азота в патогенезе болезней детского возраста. Российский вестник перинатологии и педиатрии. 2000; 4: 43–47. [Markov H.M. Pol’ oksida azota v patogeneze boleznej detskogo vozrasta. Rossijskij vestnik perinatologii i pediatrii. 2000; 4: 43–47. (In Russ)]
  14. Sargentini V., Ceccarelli G., D’Alessandro M. et al. Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study. Chem. Lab. Med. 2014; 53(4): 567–573. doi: 10.1515/cclm-2014-0119.
  15. Shears L.L., Kawaharada N., Tzeng E. et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. Clin. Invest. 1997; 100(8): 2035–2042. doi: 10.1172/JCI119736